Detalhe da pesquisa
1.
ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition.
BMC Cancer
; 21(1): 681, 2021 Jun 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34107902
2.
Bcl-XL represents a druggable molecular vulnerability during aurora B inhibitor-mediated polyploidization.
Proc Natl Acad Sci U S A
; 107(28): 12634-9, 2010 Jul 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-20616035
3.
Preclinical characterization of ABT-348, a kinase inhibitor targeting the aurora, vascular endothelial growth factor receptor/platelet-derived growth factor receptor, and Src kinase families.
J Pharmacol Exp Ther
; 343(3): 617-27, 2012 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-22935731
4.
Pyrazole diaminopyrimidines as dual inhibitors of KDR and Aurora B kinases.
Bioorg Med Chem Lett
; 22(14): 4750-5, 2012 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22695126
5.
Discovery and SAR of orally efficacious tetrahydropyridopyridazinone PARP inhibitors for the treatment of cancer.
Bioorg Med Chem
; 20(15): 4635-45, 2012 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-22766219
6.
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow.
Mol Cancer Res
; 17(2): 409-419, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30429212
7.
The PARP inhibitor, ABT-888 potentiates temozolomide: correlation with drug levels and reduction in PARP activity in vivo.
Anticancer Res
; 28(5A): 2625-35, 2008.
Artigo
em Inglês
| MEDLINE | ID: mdl-19035287
8.
Discovery and SAR of 2-(1-propylpiperidin-4-yl)-1H-benzimidazole-4-carboxamide: A potent inhibitor of poly(ADP-ribose) polymerase (PARP) for the treatment of cancer.
Bioorg Med Chem
; 16(14): 6965-75, 2008 Jul 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-18541433
9.
ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models.
Clin Cancer Res
; 13(9): 2728-37, 2007 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-17473206
10.
Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Mol Cancer Ther
; 5(4): 995-1006, 2006 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-16648571
11.
Preclinical Characterization of BET Family Bromodomain Inhibitor ABBV-075 Suggests Combination Therapeutic Strategies.
Cancer Res
; 77(11): 2976-2989, 2017 06 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28416490
12.
Molecular characterization of new melanoma cell lines from C3H mice induced by ethanol plus ultraviolet radiation.
Cancer Res
; 63(13): 3503-10, 2003 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-12839934
13.
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP Inhibitors.
Mol Cancer Res
; 13(11): 1465-77, 2015 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-26217019
14.
Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody.
Mol Cancer Ther
; 14(5): 1141-51, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25731184
15.
Pharmacodynamic evaluation of irinotecan therapy by FDG and FLT PET/CT imaging in a colorectal cancer xenograft model.
Mol Imaging Biol
; 14(5): 617-24, 2012 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-22167582
16.
Iniparib nonselectively modifies cysteine-containing proteins in tumor cells and is not a bona fide PARP inhibitor.
Clin Cancer Res
; 18(2): 510-23, 2012 Jan 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-22128301
17.
Optimization of phenyl-substituted benzimidazole carboxamide poly(ADP-ribose) polymerase inhibitors: identification of (S)-2-(2-fluoro-4-(pyrrolidin-2-yl)phenyl)-1H-benzimidazole-4-carboxamide (A-966492), a highly potent and efficacious inhibitor.
J Med Chem
; 53(8): 3142-53, 2010 Apr 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-20337371
18.
Discovery of the Poly(ADP-ribose) polymerase (PARP) inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the treatment of cancer.
J Med Chem
; 52(2): 514-23, 2009 Jan 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-19143569
19.
ABT-888 confers broad in vivo activity in combination with temozolomide in diverse tumors.
Clin Cancer Res
; 15(23): 7277-90, 2009 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-19934293
20.
Synthesis and evaluation of a new generation of orally efficacious benzimidazole-based poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors as anticancer agents.
J Med Chem
; 52(21): 6803-13, 2009 Nov 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-19888760